1. Immuneering (IMRX) is added to the Nasdaq Biotechnology Index effective December 22. 2. Index inclusion may enhance visibility and liquidity for IMRX stock. 3. Atebimetinib, IMRX's leading drug, enters Phase 3 trials for pancreatic cancer. 4. Being part of NBI reflects IMRX's compliance with stringent market requirements. 5. NBI inclusion generally positively influences investor sentiment and stock performance.
FAQ
Why Bullish?
Inclusion in the NBI enhances visibility, attracting institutional investors. Historically, stocks added to indexes often experience price appreciation, boosting IMRX's trading volume and investor interest.
How important is it?
Index inclusion typically signals growth potential and can rationalize price increases, essential for a late-stage biotech firm like IMRX.
Why Short Term?
The inclusion will affect IMRX price immediately upon announcement. Stocks usually see quick gains post-index addition, evidenced by past NBI listings.
Immuneering Corporation (IMRX) to Join Nasdaq Biotechnology Index
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology firm dedicated to improving the lives of cancer patients, has announced its upcoming addition to the Nasdaq Biotechnology Index (NBI). This transition is set to take effect prior to the market opening on Monday, December 22, 2025.
Details of the Nasdaq Biotechnology Index Inclusion
The Nasdaq Biotechnology Index is specifically designed to track the performance of publicly traded biotechnology and pharmaceutical companies. To qualify for inclusion in the NBI, firms must adhere to several eligibility criteria, including:
- Minimum market capitalization requirements
- Average daily trading volume thresholds
- Established public company status
The NBI is assessed annually each December, utilizing a modified capitalization-weighted methodology to evaluate its constituents.
For further information about the Nasdaq Biotechnology Index, please visit Nasdaq NBI Overview.
About Immuneering Corporation
Immuneering Corporation specializes in late-stage clinical oncology, specifically focusing on innovative treatment options for cancer patients. The company is pioneering a new category of cancer therapies known as Deep Cyclic Inhibitors. Its leading product candidate, atebimetinib, is an oral medication taken once daily, targeting MEK to enhance durability and tolerability for various cancer types, particularly MAPK pathway-driven tumors like pancreatic cancer.
Atebimetinib is slated for evaluation in a Phase 3 clinical trial for first-line pancreatic cancer, with dosing expected to commence in mid-2026. Alongside this flagship treatment, Immuneering is advancing early-stage therapeutic programs aimed at further solidifying its pipeline.
For more information about Immuneering Corporation and its offerings, visit www.immuneering.com.
Contact Information
For media inquiries, please contact:
Carson Creehan
Phone: 202-878-8330
Email: Carson.creehan@padillaco.com
For investor relations, please reach out to:
Laurence Watts
Phone: 619-916-7620
Email: laurence@newstreetir.com